Chronic Rhinosinusitis Trial, Recruiting NCT07446738 Sponsor: AstraZeneca Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Chronic Rhinosinusitis Trial, Recruiting

NCT07446738
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 16 years of age or older at the time of signing the consent form
  • You must have been officially diagnosed with chronic sinusitis with nasal polyps (growths inside the nose)
  • You must have a procedure to remove nasal polyps done during the initial screening period of the trial
  • You must be willing to take part and sign a consent form agreeing to participate
  • You must have no history of and no current mental health or psychiatric conditions, and be able to think clearly, communicate, and understand what is happening around you

Who may not be able to join:

  • You may not be able to join if you have any other serious illness or health condition that the trial doctor feels could put you at risk, affect the trial results, or make it difficult for you to take part (confirm with trial site)
  • You may not be able to join if you are currently taking part in another clinical trial that involves a treatment or intervention
  • You may not be able to join if you are unable to fill out questionnaires on your own due to language difficulties or problems with mental function

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Weiping Wen, Professor, First Affiliated Hospital, Sun Yat-Sen University

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
19 March 2026
Est. completion
21 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

• The observed and change from baseline of Sino-Nasal Outcome Test (SNOT)-22 score at week-52; • The observed and change from baseline of Modified Lund-Kennedy (MLK) score at week-52

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov